IRVINE, Calif.--(BUSINESS WIRE)--Jan. 16, 2006--Allergan, Inc. (NYSE:AGN) today announced that it has received final approval from the antitrust authorities in Germany and Spain in connection with its exchange offer for all outstanding shares of common stock of Inamed Corporation (NASDAQ:IMDC). The antitrust clearances in Germany and Spain are the only antitrust approvals required outside of the United States. Allergan and Inamed are continuing to work with the Federal Trade Commission staff to complete Inamed’s divestiture of its license to Reloxin(R). Such divestiture is being discussed to facilitate the antitrust approval of Allergan’s acquisition of Inamed in the United States, which is the only remaining antitrust clearance required to complete the acquisition.
